Iron Deficiency Anemia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Iron Deficiency Anemia – Pipeline Review, H1 2017’, provides an overview of the Iron Deficiency Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia

The report reviews pipeline therapeutics for Iron Deficiency Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Iron Deficiency Anemia therapeutics and enlists all their major and minor projects

The report assesses Iron Deficiency Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Galenica Ltd

Johnson & Johnson

Novartis AG

Panion & Bf Biotech Inc

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia - Companies Involved in Therapeutics Development

Galenica Ltd

Johnson & Johnson

Novartis AG

Panion & Bf Biotech Inc

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Iron Deficiency Anemia - Drug Profiles

CSJ-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-42905343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-8679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia - Dormant Projects

Iron Deficiency Anemia - Product Development Milestones

Featured News & Press Releases

Jan 12, 2017: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology

Jan 08, 2017: Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference

Jan 06, 2017: Shield Therapeutics Provides Business Update

Dec 07, 2016: EFFECT-HF demonstrates a significantly beneficial effect of Ferinject on exercise capacity among patients with chronic heart failure and iron deficiency - confirms findings of previous studies

Nov 17, 2016: Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting

Sep 07, 2016: Shield Therapeutics Announces Composition of Matter Patent Granted on Feraccru

Jun 17, 2016: Feraccru (ferric maltol) launched in the UK for the treatment of adults with iron deficiency anemia in patients with inflammatory bowel disease

Apr 28, 2016: Rockwell Medical Announces Triferic Presentation "Overcoming Functional Iron Deficiency in Your Hemodialysis Patients" at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston

Mar 29, 2016: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease

Mar 21, 2016: China FDA Accepts Rockwell Medical’s Triferic Drug Submission for Commercialization in China

Feb 26, 2016: Feraccru receives marketing authorisation in Europe

Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia

Jan 19, 2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 - May 1, 2016 in Boston, MA

Dec 18, 2015: Shield Therapeutics announces receipt of a positive opinion from the CHMP recommending the approval of Feraccru for the treatment of iron deficiency anemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Iron Deficiency Anemia – Pipeline by Galenica Ltd, H1 2017

Iron Deficiency Anemia – Pipeline by Johnson & Johnson, H1 2017

Iron Deficiency Anemia – Pipeline by Novartis AG, H1 2017

Iron Deficiency Anemia – Pipeline by Panion & Bf Biotech Inc, H1 2017

Iron Deficiency Anemia – Pipeline by Pieris Pharmaceuticals Inc, H1 2017

Iron Deficiency Anemia – Pipeline by Rockwell Medical Inc, H1 2017

Iron Deficiency Anemia – Pipeline by Shield Therapeutics Plc, H1 2017

Iron Deficiency Anemia – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports